Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06419946

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Background: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significantly enhanced when the tumor's o6-methylguanine-DNA-methyltransferase (MGMT) gene is methylated. Recent studies, such as the NOA-09 trial, have suggested that adding Lomustine (LOM) to TMZ could improve outcomes for patients with this specific tumor profile.

Hypothesis: The investigators hypothesize that the addition of LOM to the TMZ regimen will lead to significantly improved survival rates among patients with newly diagnosed glioblastoma who have a methylated MGMT promoter compared to those receiving only TMZ.

Treatment Plans: The study will randomly assign participants to two groups:

* Control Group: Standard treatment with TMZ during and after radiation therapy. * Experimental Group: TMZ combined with LOM, starting on the first day of radiation therapy.

Outcome Measures: The primary outcome measure will be survival. Other outcomes will include progression-free survival (time from randomization until tumor progression or death), safety profiles (adverse effects of the treatments), and quality of life measures as well as neurocognitive outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Glioblastoma, IDH-wildtype Astrocytoma Glioblastoma Glioma MGMT-Methylated Glioblastoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University Hospital Graz, Graz, Austria

Loading trial locations.

About this study

Current evidence:

In this section the investigators highlight the evidence behind the current standard fo care, and the emerging data supporting our approach. The RCT of Stupp showed that radiotherapy (RT) together with concomitant and adjuvant TMZ prolong survival. The NORDIC trial investigated the role of TMZ compared to RT for the subgroup of elderly patients, showing that survival was superior with TMZ, especially for those with mMGMT. LOM has been used for treatment of glioma for many decades, often used in combination with procarbazine and vincristine (PCV), but in recent years it is used in patients with glioblastoma as 2nd line therapy after failure of TMZ.

A phase 3 trial with Tumor Treating Fields (TTF, alternating low intensity electromagnetic fields) showed prolonged survival in patients with glioblastoma, but it is not universally applied/approved. Despite full multimodal treatment with surgery, RT, TMZ and TTFields, the median survival is <2 years. There is an unmet medical need to further improve treatments for these patients.

One RCT (NOA-09) provided preliminary data to exploit the specific vulnerability of mMGMT in glioblastoma (although no use of TTF in this trial). The overall tolerability of TMZ-LOM in combination was acceptable, as most adverse events (AE) were moderate and transient. Furthermore, health-related quality of life (HRQoL) and neurocognition did not differ between groups.

Estimated sample size and power:

Sample size calculation is based upon the results from the CeTeG/NOA-09 trial. Accounting for attrition, a total of 200 mMGMT GBM patients have to be randomised. Patients that drop-out before start of any therapy will be replaced, which will lead to more than 200 patients being randomized. For overall survival (OS) all patients that started day 1 of radiochemotherapy will be analysed (modified ITT). For per protocol all patients that have completed week 6 of treatment arm will be analysed for outcome. Patients lost to follow-up after the start of chemotherapy will be evaluated as observations censored at the time of dropout. Approximately 45% of newly diagnosed patients have a mMGMT, thus for 200 randomised patients a minimum of 445 patients will be screened.

Addition to the already described statistics:

Randomizations are stratified for center and for TTFields. The primary confirmatory analysis will be based on the modified intention-to-treat (mITT) population.

Survival parameters are measured in days starting from the day of randomization. Median time estimates as well as 95% confidence intervals will be reported. All additional analyses will be descriptive.

The statistical analysis plan (SAP) and blinding of statisticians will ensure analytic transparency and robustness.

Finally, similarly to avoid producing outdated results, the investigators plan to start TTF concomitant according to the Trident trial where results are expected soon. Nevertheless, if the Trident results are negative, the investigators will submit an amendment for using TTF according to the current standard of care. The reverse would not be possible in the middle of the trial as this has required extensive discussion, planning, and training with all sites. Balance with respect to TTF use is ensured with stratification in the randomization process.

Further details of study design of this phase 3, open-label, multicenter randomised controlled trial with parallel group design is presented under respective subheadings.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed glioblastoma/gliosarcoma, IDH wild type
  • Methylated MGMT promoter
  • World Health Organization performance status 0-2
  • Age 18-70

Exclusion criteria

  • Previous malignancy within 3 y or malignancy treated non-curatively
  • Previous chemotherapy or radiotherapy involving the head
  • Off-protocol tumor-specific treatment
  • Serious comorbidity

Treatment and study plan

Temozolomide

Drug

In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills

Other names: TMZ

lomustine

Drug

In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills

Other names: LOM

Primary outcomes

  1. overall survival

    Time frame: Assessed from day of randomization to event or last day of follow-up (FU). Aanlyzed 36 months after last inclusion ensures that all patients have a potential of minimum 36 months FU

    visualized with Kaplan-Meier plot, tested with log-rank test

Secondary outcomes

  1. progression free survival (PFS)

    Time frame: Assessed from day of randomization to event or last day of follow-up (FU). Aanlyzed 36 months after last inclusion ensures that all patients have a potential of minimum 36 months FU

    radiological or clinical PFS according to the modified Response Assessment in Neuro-Oncology (mRANO) criteria (Kaplan-Meier plot, log-rank test)

  2. quality of life (QoL)

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    According to the EORTC Quality of Life Questionnaire (EORTC QLQ-30) with brain cancer module 20; Evaluate minimal clinically important difference (MCID) (i.e. clinically relevant difference) according to guidelines.

    These questionnaires contain a total of 30 + 20 QoL-related questions which are scored on a nominal scale (0-5 points); the result of each question is recorded for computerized examination and the questions relating to the same dimension of QoL (e.g. emotional well-being) are taken together for an overall score of this dimension. The scores for the different dimensions will be compared between repeated assessments throughout the trial and between the two arms of the trial.

    Analysed at 8 different time points:

    • start of therapy = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

  3. neurocognition - verbal memory

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Verbal Memory Test: Participants are tasked with learning and recalling 15 words. They are asked to recognize the words among 15 distractors (other words). The test is repeated at the end of the test session (after approximately 30 minutes). This test measures how well the participant can learn and recall words. Low scores indicate verbal memory difficulties.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  4. neurocognition - visual memory

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Visual Memory Test: Participants are tasked with learning and recalling 15 geometric shapes. They are asked to recognize these among 15 distractors (other shapes). The test is repeated at the end of the test session (after approximately 30 minutes). This test measures how well the participant can learn and recall geometric shapes. Low scores indicate visual memory difficulties.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs" (CNS = central nervous system), a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  5. neurocognition - motor speed and fine motor control

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Finger Tapping Test: The test measures motor speed and fine motor control. Participants are to perform three "tapping" sessions, lightly tapping the top of a key on the computer with each hand. This test measures how many "tappings" the participant performs with each hand. Motor speed varies according to hand dominance. Low scores indicate motor slowing.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  6. neurocognition - cognitive speed

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Symbol Digit Coding: The test measures cognitive speed during simultaneous cognitive processes such as visual scanning, visual perception, visual memory, and motor skills. Low scores may indicate impulsivity, perception difficulties, or impaired processing speed.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  7. neurocognition - simple and complex reaction time, inhibition/disinhibition, mental flexibility, and focused attention.

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Stroop Test: The test measures simple and complex reaction time, inhibition/disinhibition, mental flexibility, and focused attention. It also measures how well participants can adapt to changes and increasing complexity in the task. Long reaction times indicate mental slowing. A large number of errors indicate impulsivity, perception difficulties, or impaired processing speed.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  8. neurocognition - attention

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Attention Shift Test: The test measures how well participants can shift attention and perform simultaneous tasks. Participants must adjust their responses to temporarily changed rules. Normal/good scores are achieved with a high proportion of correct answers and short reaction times.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  9. neurocognition - attention, vigilance, and reaction time

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Continuous Performance Test: The test measures attention, vigilance, and reaction time. Most normal participants achieve nearly perfect results on this test. Long response times indicate mental slowing or impaired attention.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  10. neurocognition - Perception

    Time frame: done at baseline after informed consent, before randomisation and start of treatment, week 6 from start of treatment= end of radiotherapy, and every 24 weeks from start of treatment and for max 36 months.

    Emotional Perception Test: The test measures how well participants can perceive and identify specific emotions and their ability to perceive and understand social information. Low scores indicate difficulties with emotional perception.

    Analysed at 8 different time points:

    • start of therapy (RT/chemotherapy/TTFields) = day 1
    • since first assessment 6 weeks later: middle of the first months (1.5)
    • from now on, every 6 months: month 7.5
    • month 13.5
    • month 19.5
    • month 25.5
    • month 31.5
    • month 37.5 (end of the follow-up after 4 years)

    Patients will be monitored with the "CNS Vital Signs", a validated computerized test battery with proven sensitivity to detect cognitive impairments in patients with brain tumors. The battery consists of 8 subtests.

  11. Adverse events (AE)

    Time frame: assessed from day of randomization to death or 36 months FU

    according to the Common Terminology Criteria for Adverse Events (CTCAE). (descriptive statistics between groups). A complementary analysis of AE by severity of event and by relationship to treatment will be performed (Chi2 test). Dose reductions, delay of therapy in subsequent courses and premature withdrawals will also be described.

    The Pharmacovigilance Sahlgrenska University Hospital will provide an unbiased evaluation of all serious adverse events. This ensures a qualified evaluation to support the sponsor to ensure patient safety. A Data Safety Monitoring Board (DSMB) is appointed to perform pre-planned interim analyses. Prompt ad-hoc meeting of the DSMB will be held in case of suspected unexpected serious adverse events. The committee can recommend a break or the stopping of the trial.

Study contacts

Contact information is provided by the study sponsor or research team.

Annika Malmström, MD. PhD

CONTACT

[email protected]

Asgeir S Jakola, MD, PhD

CONTACT

[email protected]

+46313429741

Sponsors and collaborators

Lead sponsor

Vastra Gotaland Region

Other Gov

Collaborators

  • Aarhus University Hospital
  • Gävle Hospital
  • Haukeland University Hospital
  • Helse Stavanger HF
  • Kalmar County Hospital
  • Karolinska Institutet
  • Kepler University Hospital
  • Oslo University Hospital
  • Region Örebro County
  • Ryhov County Hospital
  • Sahlgrenska University Hospital
  • Skane University Hospital
  • Sorlandet Hospital HF
  • St. Olavs Hospital
  • Sundsvalls Hospital
  • University Hospital of Sankt Pölten
  • University Hospital, Umeå
  • Universitäts-Frauenklinik Graz
  • Uppsala University Hospital
  • medizinische universität innsbruck, Austria

Registry information

Official study title

Phase III Trial of Temozolomide/Lomustine (TMZ/LOM) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT Promoter Methylated Glioblastoma (IDHwt) Patients +/- Tumor Treating Fields (Optune)

Important dates

Study start
2025
Primary completion
2031
Study completion
2033
First posted
May 17, 2024
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.